Introduction {#s1}
============

Malaria control and elimination remain a significant public health challenge, and an effective malaria vaccine targeting *Plasmodium falciparum* (Pf) would be an important tool to accelerate burden reduction, curb the spread of drug resistant strains and facilitate focal Pf malaria elimination ([@bib24]). While the most advanced vaccine, RTS,S/AS01A, an adjuvanted subunit vaccine for pediatric indications based on the major Pf sporozoite surface protein ([@bib2]), is currently being assessed in a large pilot study for safety, impact, and feasibility of routine immunization of children ([@bib59]), other vaccines are in development or currently tested. The Malaria Vaccine Roadmap provides guidance for next-generation vaccine development targeting all age groups with improved efficacy and extended duration of protection ([@bib37]). However, although extensive work has been undertaken to understand potential immune mechanisms of vaccine-induced protection against malaria infection and disease, much remains unknown.

An alternative to the subunit vaccine approach is immunization with attenuated whole Pf sporozoite vaccines ([@bib45]). Malaria sporozoites have been studied in the context of inducing sterile immunity first in mouse models ([@bib41]), and later in humans via Pf-infected mosquitoes ([@bib9]; [@bib46]; [@bib26]). Whole sporozoite malaria vaccine development is currently based on aseptic, purified, metabolically active Pf sporozoites (NF54 strain), either radiation-attenuated (PfSPZ Vaccine), chemo-attenuated through concurrent antimalarial administration (PfSPZ-CVac), or genetically modified (PfSPZ-GA2) ([@bib45]). Clinical trials have evaluated the efficacy of PfSPZ Vaccine (e.g. [@bib19]; [@bib48]; [@bib28]; [@bib20]; [@bib35]) resulting in evidence that intravenous injections provide higher protection than intradermal applications against homologous and heterologous CHMI. Specifically, all US adults (n = 6) volunteers were protected against homologous CHMI in a 5-dose schedule ([@bib48]), of whom 5 of 6 remained protected following CHMI at 59 weeks after last immunization ([@bib28]). Protection following heterologous CHMI (7G8 strain) has been achieved for up to 33 weeks after last vaccine dose ([@bib20]; [@bib35]). These results enabled the PfSPZ Vaccine to receive an FDA Fast Track designation ([@bib47]).

To evaluate the protective efficacy against CHMI of PfSPZ Vaccine in malaria pre-exposed volunteers, PfSPZ Vaccine was evaluated in a dose-escalation study in a cohort of adult, male Tanzanian volunteers (acronym: BSPZV1) ([@bib29]). In this study, vaccine-induced protection against homologous CHMI was assessed for the first time in Sub-Saharan Africa by direct venous inoculation (DVI) of 3200 fully infectious sporozoites (PfSPZ Challenge) three and/or 24 weeks after last immunization. 1/18 volunteers who received 5 doses of 1.35 × 10^5^ PfSPZ (group 2,) and 4/20 volunteers who received 5 doses of 2.7 × 10^5^ PfSPZ (group 3) were sterilely protected 3 weeks after last vaccine dose. The four individuals from the higher dose group protected in the first CHMI remained protected at a second CHMI conducted 24 weeks after final PfSPZ immunization ([@bib29]).

Our understanding of naturally or vaccine induced cellular immune dynamics has considerably improved over the years, however much remains unknown. The immune mechanisms conferring protection associated with PfSPZ Vaccine have been studied in mouse and non-human primate models, and in human biological specimens ([@bib33]). In mice, the role of liver resident CD8+, IFNγ producing T cells, and γδT Cells have been considered paramount for conferring protection ([@bib33]), but their role in humans remain more difficult to assess. Pf-specific T cells found in peripheral blood might not represent the more abundant and stable tissue resident effector T cells ([@bib28]), and thus might not represent a good proxy for cellular immunity in the liver. CD4 and CD8 T cells producing IFNg, interleukin 2 (IL2) and tumor necrosis factor alpha (TNFa) were detected in peripheral blood after immunization of malaria naïve volunteers, however, their levels rapidly declined over time and were not correlated with protection ([@bib28]; [@bib35]). No increase in CD8 T cell responses was observed following immunization of Tanzanian volunteers, and CD4 levels increased to lower magnitudes compared to malaria naïve individuals, with no association with protection ([@bib30]).

There has been significant work to assess the quality and quantity of antibody responses following PfSPZ Vaccine application. IgG specific to the Pf circumsporozoite protein (CSP) measured by ELISA or detected against PfSPZ by automated immunofluorescence assay (aIFA) correlated with protection in malaria naïve volunteers at 3 week and 21--25 week post-vaccination homologous CHMI in one study ([@bib28]). In contrast, the PfCSP ELISA and PfSPZ aIFA trend was not significant when the sporozoite dose was increased to 9 × 10^5^ PfSPZ administered three times ([@bib35]), and these assays, along with an inhibition of sporozoite invasion (ISI) assay, did not correlate with protection in follow up studies ([@bib20]).

A functional role of antibodies in protection after PfSPZ Vaccination was proposed after passive transfer of the IgG fraction of immune sera from protected volunteers into humanized FRG-huHep mice that led to an 88% and 65% reduction in parasite liver burden with immune sera collected 2--3 weeks and 59 weeks after last PfSPZ immunization, respectively ([@bib28]). Further evidence of functional activity of humoral immunity was shown with anti-PfCSP monoclonal antibodies (mAbs) isolated from Tanzanian volunteers ([@bib53]) and from U.S. vaccinees ([@bib32]). Additionally, IgM specific to PfCSP was detected in Tanzanian pre-exposed adult males after immunization with PfSPZ Vaccine, and these IgM inhibited liver cell sporozoite invasion in vitro and fixed complement on whole Pf sporozoite ([@bib61]). Antigen-specific humoral immune responses have been studied in clinical trials by ELISA for a selection of antigens, such as PfCSP, PfEXP1, PfEBA-175, PfLSA1, PfMSP1 and PfMSP3 (see [@bib20] for summary of findings). However, the number of antigens that can be assessed in parallel with ELISA is limited and thus constrained to pre-selected of antigens.

In contrast, malaria protein microarrays enable a less biased approach to assess humoral immunity against a large proportion of Pf encoded proteins ([@bib34]). This technology has assessed potential boosting of natural immunity in RTS,S vaccinated individuals ([@bib7]), and was used to better understand the natural history of malaria infection in the field ([@bib6]). Microarrays have also identified immune-reactive antigens associated with malaria exposure for immune-epidemiological studies, or to examine potential correlates of protection in children and adults from endemic areas ([@bib15]). Serum samples from malaria-naïve individuals infected by radiation-attenuated sporozoites via mosquito bites have been probed with microarrays covering 23% of all Pf proteins, providing insight into humoral immunity induced by both whole sporozoite vaccination and its association with sterile protection following CHMI ([@bib55]). More recently, a whole proteome microarray produced by Antigen Discovery, Inc (ADI) that includes 91% of all predicted Pf 3D7 strain proteins was used to study humoral immunity after PfSPZ-CVac vaccination in European malaria-naive volunteers ([@bib38]). 22 proteins were identified, which were recognized by more than 50% of the volunteers in the highest dose group, all of whom were protected against homologous CHMI ([@bib38]).

The main *in-vitro*, animal, and human studies described above suggest that both cellular immune response and antibody mediated immune response plays a role in inducing protection. However, a complete understanding of the mechanisms of vaccine-induced protection against malaria infection, and its interplay with pre-built natural immune response in exposed populations, remains unknown. For a comprehensive and unbiased description of Pf-specific humoral immune responses in malaria pre-exposed volunteers, we analyzed serum samples using the Pf protein microarray featuring 7455 full-length or fragmented proteins of the Pf proteome (3D7) ([@bib38]). Serum samples were collected pre-vaccination and 14 days past last vaccination to understand the PfSPZ Vaccine-induced IgG profiles in Tanzanian male adults participating in the BSPZV1 study and potential correlations between humoral immune responses and PfSPZ vaccine induced protection against homologous CHMI ([@bib29]). We show for the first time that our study population displayed highly personalized immune profiles based on a broad range of antigens recognized before vaccination. Surprisingly, this humoral immune pattern remained largely unchanged following the whole organism based PfSPZ immunization, leading to the hypothesis of natural imprinting of humoral immune responses.

Results {#s2}
=======

Study volunteers and serum sampling {#s2-1}
-----------------------------------

In total, 92 serum samples from 46 volunteers enrolled in the BSPZV1 study (all volunteers from group 2 and group 3 in the clinical trial \[[@bib29]\]) were probed on Pf whole proteome microarrays, including samples collected at baseline (before vaccination) and 2 weeks after last immunization ([Figure 1](#fig1){ref-type="fig"}). Eight non-vaccinated placebo controls, 18 volunteers who were immunized with the lower PfSPZ Vaccine dose (group 2) and 20 volunteers who received the higher PfSPZ Vaccine dose (group 3) were included ([Figure 1](#fig1){ref-type="fig"}; [@bib29]). All volunteers included in the study had no parasitemia at the start of the study (measured by malaria thick blood smears (TBS)) and no parasitemia before CHMI (measured by TBS and the more sensitive qPCR) ([@bib29]). Additional exclusion criteria included history of malaria in the previous 5 years or antibodies to PfEXP1 by ELISA above a threshold level ([@bib29]) associated with recent infection by CHMI ([@bib49]).

![Sampling and volunteer information for proteome microarray studies.\
Three arms of a randomized, double-blind Phase 1 trial of PfSPZ Vaccine were selected for antibody profiling on Pf whole proteome microarrays: normal saline controls, a lower dose (group 2, 1.35 × 10^5^ PfSPZ Vaccine/dose) and a higher dose (group 3, 2.7 × 10^5^ PfSPZ Vaccine/dose). Serum samples were collected before immunization and 2 weeks after the final immunization. Information on the protection status of the volunteers after a 3 week post-immunization CHMI is provided. ^\#^Masking included participant, care provider, investigator and outcome assessor. \*Samples were unavailable for protein array screening from two group 2 volunteers, one did not receive the 5^th^ immunization dose and one left the country before CHMI ([@bib30]). All volunteers in the clinical trial who received 5 doses of immunization and who underwent CHMI 3 weeks after last immunization dose were included in the current analysis.](elife-53080-fig1){#fig1}

Tanzanian male adults recognize a high diversity of pf proteins {#s2-2}
---------------------------------------------------------------

Across the 7455 Pf full length or fragmented proteins, 2804 probes corresponding to 2239 Pf proteins were considered as reactive antigens in the 92 samples tested for having a seropositive response (normalized signal intensity ≥1) in at least 10% of volunteers at either or both time points.

First, we examined the antibody profiles for each volunteer individually and the results of the paired samples are presented in the heatmap ([Figure 2a](#fig2){ref-type="fig"}). Pattern of antigens recognized across all peptides was largely unchanged before and after immunization. This was further confirmed by applying a dimensionality reduction algorithm (t-Distributed Stochastic Neighbor Embedding (t-SNE)) to represent the 2804 probes recognized in two dimensions and including time points assessed ([Figure 2b](#fig2){ref-type="fig"}). The t-SNE algorithm estimates the probability distribution of neighbors around each point, that is, it models the set of points which are closest to each point. A distinct clustering of observations for 43 out of the 46 volunteers was evident, with each pair of sample's nearest neighbor in the first two dimensions as the corresponding sampling time point for that volunteer ([Figure 2b](#fig2){ref-type="fig"}). Volunteer samples did not cluster according to treatment allocation with no difference identified by t-SNE between controls and vaccinees, but rather volunteers preserved their immunoreactive 'fingerprint' measured in their samples taken at baseline and two weeks following last PfSPZ Vaccination. It was not obvious why these three subjects did not maintain longitudinally consistent antibody profiles and we cannot rule out technical or sampling issues, or if they are due to unidentified biological factors associated with vaccination or temporal immune status. However, our results show these three individuals had slightly higher than average baseline antibody breadth and steeper decrease of breadth after immunization ([Figure 3c](#fig3){ref-type="fig"}).

![Antibody immune profile of Tanzanian healthy male adult volunteers is personalized.\
The heatmap of the normalized signal intensities of each sample per subject is shown in (**a**), with the signal intensity of each protein or fragment (rows) displayed for the samples before and after immunization of each volunteer (columns). The colored column headers represent volunteers ordered according to treatment allocation. 8 subjects of the control group (black), CHMI unprotected subjects of group 2 (n = 17, yellow), unprotected subjects of group 3 (n = 16, blue), CHMI protected subjects (n = 5, green). The first and second columns for each subject display the results obtained from baseline and after immunization samples, respectively. The \# indicates volunteers BSPZV1-360, BSPZV1-104 and BSPZV1-117. (**b**) A t-SNE projected dimensionality reduction of normalized signal intensities across the microarray spots measured at baseline (triangles) and after PfSPZ vaccination (crosses) is shown. In (b-*i*) data are shown for the total 2804 reactive spots and in (b-*ii*) for the subset of 441 reactive proteins fragments predicted to be expressed at the sporozoite stage ([@bib22]), with the signals obtained for each subject at the two bleeding time points grouped in circles. For 3 out of 46 subjects, namely BSPZV1-360, BSPZV1-104 and BSPZV1-117, the signals do not cluster in this t-SNE analysis.\
Figure 2---source data 1.Data frame of the normalized signal intensities of the protein microarray.This table includes log~2~ signal intensities of each of the 7'455 protein spots for all samples. Serum draw, immunization dose, protection after CHMI, and description of each protein fragment are specified.](elife-53080-fig2){#fig2}

![Breadth of Pf-specific humoral immunity upon PfSPZ vaccination.\
Breadth of Pf-specific antibody responses per volunteer (**a**) before and (**b**) after PfSPZ vaccination, stratified according to intervention and ordered according to their respective number of seropositive responses from highest to lowest. In (**c**) boxplots show median, interquartile range (IQR) and 1.5xIQR limits of the antibody breadth grouped by study arm and time point, means for each group are represented by red lines, and an estimated fold change with p-value from the inverted beta-binomial test are indicated for each group. Breadth of each volunteer are indicated by dashed lines. Controls, group 2 (1.35 × 10^5^ PfSPZ Vaccine/dose) and group 3 (2.7 × 10^5^ PfSPZ Vaccine/dose) volunteers are marked in black, yellow and blue, respectively. Results of the five CHMI protected individuals are highlighted in green (light green in group 2).\
Figure 3---source data 1.Breadth of Pf-specific humoral immunity in each sample.\
Figure 3---source data 2.Summary statitistics on breadth per group and protection level.An estimated effect of immunization on breadth and corresponding p-value performing the inverted beta-binomial test for paired count data using sample at basdeline and after immunization are shown in **A**, together with the mean and median breadth for each group at baseline and after immunization, and for the protected and unprotected group. (**B**) indicates the estimated regression coefficient and corresponding p values of the negative binomial regression to test differences in breadth between two groups at either baseline or after immunization.](elife-53080-fig3){#fig3}

To further investigate the breadth of humoral immune response against the 2804 peptides, the total number of peptides regarded as sero-reactive per sample were analyzed ([Figure 3](#fig3){ref-type="fig"}). Antigen recognition varied widely among individuals, with breadth of humoral immune response ranging from 187 to 2360 reactive antigens across all samples before immunization, and from 217 to 1535 and 187 to 1965 reactive antigens per volunteer in group 2 and group 3, respectively, after PfSPZ Vaccination ([Figure 3a--b](#fig3){ref-type="fig"}). Median antibody breadth from the PfSPZ-immunized volunteers across both immunization groups was 720 and 669 reactive peptide features recognized before and after immunization, respectively.

The effect of vaccination on breadth was analyzed by comparing breadth between the control and the PfSPZ Vaccine-immunized groups, and by quantifying the change in breadth after immunization compared to baseline levels. No significant differences in antibody breadth between the control and group 2 or group 3, nor between group 2 and group 3 after vaccination were detected (results of the negative binomial regression summarized in Table supplement 1). During the period before and after vaccination, antibody breadth declined in many individuals in the control and immunized groups (note that samples were balanced for group and time point factors across technical microarray factors using a block randomization design, see Materials and methods), the relative differences in the medians between the two time points were of −4.8%, −13.6% and −4.7% seropositive signals in the control, group 2 and group 3, respectively (effect of vaccination on breadth tested with the inverted beta-binomial test for paired count data, resulting in an estimated fold change of −1.23,--1.16 and 1.03, and a p-value of 0.24, 0.03 and 0.43, respectively) ([Figure 3c](#fig3){ref-type="fig"}). In controls, 2/8 volunteers (25%) had higher antibody breadth after placebo inoculation compared to baseline ([Figure 3c](#fig3){ref-type="fig"}), and antibody breadth after PfSPZ Vaccine immunization increased in 6/18 (34%) and 12/20 (60%) individuals in group 2 and group 3, respectively ([Figure 2c](#fig2){ref-type="fig"}). Note that the volunteers for which samples that did not cluster in the t-SNE outputs appear to have higher than average baseline breadth and steeper decrease of breadth after immunization ([Figure 3c](#fig3){ref-type="fig"}). Overall, there was no dramatic change in breadths between both time points, which aligns with the immune fingerprint analysis in [Figure 2](#fig2){ref-type="fig"}. There was a small decreased average breadth in group 2 driven by 2 of the three individuals whose samples did not cluster for immune-fingerprinting.

To assess the biological characteristics of this large number of reactive proteins, we used the DeepLoc method for *in silico* prediction of protein subcellular localization using the 3D7 protein amino acid sequences ([@bib1]; [Table 1](#table1){ref-type="table"}). Numerous reactive proteins predicted to be exported (*n* = 53) or cell membrane associated (*n* = 208) were identified. The majority of reactive antigens were predicted to be intracellular proteins (*n* = 1978). However, many of the well-known proteins present in the parasite organelles such as rhoptries and micronemes and proteins exported to the surface of infected erythrocytes such as PfEMP1 variants were predicted to be localized intracellularly, which shows that the currently available prediction algorithms remain limited by complex parasite biology. The full list of reactive antigens and DeepLoc subcellular localization predictions is shown in [Table 1---source data 1](#table1sdata1){ref-type="supplementary-material"}.

###### Intracellular proteins are the most abundant reactive proteins.

The frequencies of reactive antigens allocated into the different subcellular localization categories (rows) for each group (columns), tested using 2-propotions Z-test and p-values adjusted using the Benjamini-Hochberg method (BH) ([@bib5]), are shown (for all reactive proteins with p-values\<0.05). Column two indicate the total number of reactive antigens, and columns 3--8 detail the number of significantly differentially reactive proteins localized in each compartment across samples before immunization, after immunization, in the protected group before and after immunization, in the unprotected group before and after immunization, respectively. The first row shows extracellular proteins, the second row is cell membrane associated proteins and the following rows are predicted intracellular proteins split according to subcellular localisation. The percentage of the reactive proteins found in each group compared to all samples (first column) are indicated in parenthesis.

Table 1---source data 1.The full list of reactive antigens and DeepLoc subcellular localization predictions.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             Subcellular\    *N* reactive\   Baseline\    Post-Immz\   Baseline reactivity\   Post-Immz reactivity\   Baseline reactivity\   Post-Immz reactivity\
                             localization    proteins        reactivity   reactivity   (protected)            (protected)             (unprotected)          (unprotected)
  -------------------------- --------------- --------------- ------------ ------------ ---------------------- ----------------------- ---------------------- -----------------------
                             Extracellular   53              3 (6%)       3 (6%)       10 (19%)               12 (23%)                3 (6%)                 3 (6%)

                             Cell membrane   208             11 (5%)      8 (4%)       63 (30%)               70 (34%)                10 (5%)                5 (2%)

  Intracellular (N = 1978)   Cytoplasm       661             14 (2%)      16 (2%)      73 (11%)               79 (12%)                12 (2%)                14 (2%)

  Endoplasmic reticulum      429             12 (3%)         11 (3%)      53 (12%)     60 (14%)               11 (3%)                 10 (2%)                

  Golgi apparatus            76              2 (3%)          2 (3%)       13 (17%)     15 (20%)               2 (3%)                  2 (3%)                 

  Lysosome/Vacuole           32              1 (3%)          1 (3%)       3 (9%)       2 (6%)                 1 (3%)                  1 (3%)                 

  Mitochondrion              150             3 (2%)          3 (2%)       11 (7%)      14 (9%)                3 (2%)                  3 (2%)                 

  Nucleus                    624             24 (4%)         20 (3%)      107 (17%)    115 (18%)              17 (3%)                 18 (3%)                

  Peroxisome                 3               0 (0%)          0 (0%)       0 (0%)       0 (0%)                 0 (0%)                  0 (0%)                 

  Plastid                    3               2 (67%)         2 (67%)      2 (67%)      2 (67%)                2 (67%)                 2 (67%)                

                             Total           2239            72 (3%)      66 (3%)      335 (15%)              369 (16%)               61 (3%)                58 (3%)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Moderate increase in antigen recognition following immunization with PfSPZ vaccine {#s2-3}
----------------------------------------------------------------------------------

To investigate potential vaccine induced increase in antigen immunogenicity, we compared mean reactivity of each antigen 2 weeks after immunization in relation to the baseline responses, grouped according to treatment intervention ([Figure 4a--c](#fig4){ref-type="fig"}). Reactivity against most antigens decreased after immunization in group 2 and in the placebo group during the \~24 week time interval between the two comparison time points, although not significantly when adjusted for the false discovery rate (FDR) with the Benjamini-Hochberg method (BH) ([@bib5]; [Figure 4a,b](#fig4){ref-type="fig"}), which aligns with the observed slight decrease in breadth of immune response following immunization. Antibodies binding to the Pf circumsporozoite protein (CSP) increased in group 2 and higher in group 3, although not significantly when adjusted for FDR (unadjusted p-value of 4.4 ∗ 10^-4 ^\[adjusted: 0 .42\] and 2.1 ∗ 10^−5^ \[adjusted: 0.06\] for the t-test in group 2 and group 3, respectively) ([Figure 4c](#fig4){ref-type="fig"}). The mean negative value for PfCSP immunogenicity at baseline (before immunization, mean intensity = −0.73) suggests that very limited anti-PfCSP responses existed at baseline, with no significant differences between the study groups observed. Notably, the nonsignificant trend for reactivity decline observed in controls in almost all protein fragments of group 2 was not present in group 3.

![Increase in antigen recognition from baseline to after PfSPZ vaccination is moderate.\
The three volcano plots in the upper row show (**a**) the mean fold change in the control group (n = 8), (**b**) in group 2 (1.35 × 10^5^ PfSPZ Vaccine/dose) (n = 18), and (**c**) in group 3 (2.7 × 10^5^ PfSPZ Vaccine/dose) (n = 20). In all groups, the samples collected at baseline and two weeks past last vaccination were compared. The dashed line represents the threshold of statistical significance (p=0.05) not adjusted for the FDR (none of the antigens had a FDR adjusted p-value\<0.05). For effect size estimates see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.\
Figure 4---source data 1.Source data for plot **a**.\
Figure 4---source data 2.Source data for plot **b**.\
Figure 4---source data 3.Source data for plot **c**.](elife-53080-fig4){#fig4}

'Deltas', the fold change in antibody reactivity (averaged across each individual group) for each individual peptide recognized before and after immunization, was higher for PfCSP in group 2 and group 3 when compared to controls, but not statistically significant after adjustment ([Figure 4---figure supplement 2a--b](#fig4s2){ref-type="fig"}). In addition, no significant difference was observed by comparing group 2 deltas to group 3 deltas [Figure 4---figure supplement 2c](#fig4s2){ref-type="fig"}). The nonsignificant trend of higher deltas in group 3 is consistent with the observations of less declining antibodies in the paired analysis.

To identify potential differences in vaccine induced immunogenicity between protected and unprotected individuals, we compared the difference in the mean immunoreactivity (i.e. signal intensity) for each antigen at baseline and 2 weeks after immunization between protected (n = 5) and unprotected (n = 33) volunteers, and the difference in the mean immunogenicity of each antigen between baseline and post immunization time points in the protected group ([Figure 5](#fig5){ref-type="fig"}). Four proteins were recognized as significantly higher in the protected volunteers after immunization compared to unprotected volunteers ([Figure 5b](#fig5){ref-type="fig"}). These proteins were the apical membrane antigen 1 (PfAMA1, gene ID PF3D7_1133400) and 3 fragments of the erythrocyte membrane protein 1 (PfEMP1, gene IDs PF3D7_0412900, PF3D7_1240400 and PF3D7_0711700). Interestingly, amino acid sequence alignment of the three identified PfEMP1 protein fragments with the predicted sporozoite encoded variant PF3D7_0809100, recently described to contribute to inhibition of hepatocyte invasion ([@bib60]), demonstrated long stretches of linear protein sequence conservation ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Nevertheless, the sample size of the protected group is low (n = 5), and considering the low effect size measured by Cohen's distance ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), no strong argument for association with protection of these four antigens can be made from this analysis. The mean immunogenicity of PfAMA1 and PfCSP levels across the protected group increased from baseline to after immunization, but not reaching the significance threshold ([Figure 5c](#fig5){ref-type="fig"}). Notably, a trend of higher reactivity levels to the 3 PfEMP1 fragments in the protected group was observed at baseline, albeit not significantly ([Figure 5a](#fig5){ref-type="fig"}). No antigen showed an increase in reactivity (delta) significantly higher in the protected group ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

![The five volunteers protected against homologous CHMI showed higher recognition of four distinct proteins after immunization.\
The mean fold change between antigen reactivity in the protected (n = 5) and the non-protected (n = 33) individuals from groups 2 and 3 are represented in volcano plots (**a**) for baseline and (**b**) after PfSPZ vaccination, plotted against the inverse log~10~ t-test p-value. In the protected group (n = 5), the samples collected at baseline and two weeks past last vaccination were compared and the mean fold change of the increased immunogenicity is showed in (**c**). Red triangles represent antigens with significant differences in antibody levels between protected and non-protected volunteers after BH adjustment of p-values, although size effect measured by Cohen's distance remains low (see [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). The dashed line represents the threshold of statistical significance for the unadjusted p=0.05.\
Figure 5---source data 1.Source data for plot **a**.\
Figure 5---source data 2.Source data for plot **b**.\
Figure 5---source data 3.Source data for plot **c**.](elife-53080-fig5){#fig5}

Breadth of humoral immune response in protected individuals {#s2-4}
-----------------------------------------------------------

Analysis above indicates that breadth of humoral immune response was highly variable in samples across all groups and mostly conserved from baseline to post-immunization levels, irrespective of protection status ([Figure 3](#fig3){ref-type="fig"}). We thus further compared breadth of humoral immune response in the protected versus unprotected individuals. Despite a mean breadth in the protected group 12% higher than in the unprotected individuals before immunization (breadth~protected~ = 914, breadth~unprotected~ = 810) and 28% higher after immunization (breadth~protected~ = 943, breadth~unprotected~ = 738), as antibody breadth was highly over-dispersed and sample size in the protected group small we found that differences in the means are not significant for either time points (logistic regression p-values of 0.6 and 0.3, respectively) ([Figure 6](#fig6){ref-type="fig"}). Furthermore, there was also limited discrimination by protection status in antibody breadth at both time points via receiver operating characteristics (ROC) analysis (area under the ROC curve: AUC~pre-immunization~ = 0.64, Wilcoxon rank sum test *W* = 60, p-value=0.35; AUC~post-immunization~ = 0.73, Wilcoxon rank sum test *W* = 44, p-value=0.1).

![Breadth and magnitude of Pf-specific humoral immunity in protected and unprotected individuals.\
(**a**) Breadth counts of all PfSPZ vaccinees grouped by protection status following CHMI, with protected group in green and non-protected volunteers depicted in white, before and after immunization. The coefficient estimate with corresponding p-values from the negative binonial test is indicated for each time point. Boxplots show median, interquartile range (IQR) and 1.5xIQR limits and red bars represent the mean.](elife-53080-fig6){#fig6}

Finally, in order to identify antibodies consistently present in the samples of the protected individuals, we defined common antigens to a group as antigens which are reactive in at least 80% of the samples for each of the groups (i.e. considering the signal intensity of a given antigen as a binary outcome, either reactive or non-reactive). Common antigens in the protected group (reactive in at least 4 out of the five samples) were higher than in the unprotected groups (reactive in at least 27 out of the 33 samples) both 2 weeks after last immunization (383 common antigens in the protected group versus 58 in the unprotected group, 2-sample test for equality of proportions with continuity correction p-value\<2.2E-16, *N* = 2804) ([Figure 7b](#fig7){ref-type="fig"}), and at baseline (350 reactive antigens in protected group versus 62 in unprotected group, p\<2.2E-16) ([Figure 7a](#fig7){ref-type="fig"}). Both at baseline and 2 weeks after immunization, almost all reactive antigens in common in the unprotected group were also present in the protected group (60 out of 62 and 56 out of 58 antigens at baseline and after immunization, respectively) ([Figure 7](#fig7){ref-type="fig"}). The trend for higher common antigens in the protected group compared to the unprotected group was also noticeable for different thresholds, comparing antigens reactive in at least 60% or in 100% of the samples in a given group ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Given the large difference in sample sizes between the protected (n = 5) and unprotected (n = 33) groups, bootstrap samples with n = 5 samples in each group were repeatedly drawn (repeated 1000 times), with replacement. Consistent with previous analyses above, we find a higher number of common antigens in the protected compared to the unprotected group, although uncertainty due to small sample size is inevitable ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Taken together this analysis suggests a higher number of commonly recognized antigens in the protected individuals after immunization and also at baseline, but the findings are limited by a small sample size in the protected group. A list of the commonly reactive antigens and antigens with increased reactivity levels following immunization per groups can be found in the [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}.

![Protected individuals showed higher numbers of reactive antigens compared to the non protected group.\
The number of antigens that were reactive in at least 80% of the individual in each group are represented for (**a**) baseline for the protected group (green, n = 5) and the unprotected group (grey, n = 33) and for (**b**) after immunization for the protected group (green) and unprotected group (grey).\
Figure 7---source data 1.Table of commonly recognized antigens .List of the antigens that increased in reactivity following immunization, or that were reactive after immunization in at least 50% (highlighted in blue) of a given group are listed, including the ID, gene ID, Description, and the number of volunteers for which the antigen was reactive or had increased reactivity following immunization.](elife-53080-fig7){#fig7}

To understand the biological function of proteins reactive in protected volunteers, we used DeepLoc subcellular localization prediction, Pfam protein family prediction ([@bib18]), and gene ontology prediction available on [Plasmodb.org](http://Plasmodb.org) ([@bib27]) and identified protein characteristics and distinct functional categories with higher representation in the protected volunteers. Predicted cell membrane proteins were more broadly recognized in the five protected volunteers at baseline (63 vs. 10 proteins, 2-proportions Z-test p-value=2.53E-9) and post-immunization (70 vs. 5 proteins, p-value=4.11E-13), but so were intracellular proteins localized to the cytoplasm, endoplasmic reticulum, Golgi apparatus, mitochondrion and nucleus (all p-values\<0.05) ([Table 1](#table1){ref-type="table"}). Gene and protein families present in both protected and non-protected groups at both time points included integral components of membranes, host cell plasma membranes and infected host cell surface knobs, signal receptor activity and cell adhesion molecule binding, pathogenesis, cell-cell adhesion, antigenic variation and cytoadherence to the microvasculature, and PfEMP1-related families (see [Supplementary file 1](#supp1){ref-type="supplementary-material"}) . Gene and protein families uniquely reactive in the protected volunteer group at either or both time points included Mauer's cleft, host cell surface receptor binding, regulation of immune response, the Rifin protein family, a head domain of trimeric autotransporter adhesins (TAAs) family that acts as virulence factors for Gram-negative bacteria and have a head-stalk-anchor structure, a procyclic acidic repetitive protein family that was identified as abundant surface proteins in *Trypanosoma brucei*, and an N-terminal PRP1 splicing factor family involved in mRNA splicing ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}).

Discussion {#s3}
==========

We provide first time data on the proteome-wide antibody profiling study for malaria endemic populations enrolled in a PfSPZ Vaccine phase Ib trial with homologous CHMI. Our analysis provides not only insights to PfSPZ vaccine induced humoral immune response and potential association with protection, but also a comprehensive view of underlying naturally acquired immunity in healthy Tanzanian adult men. The protein microarray used in this study considered a near full-proteome coverage ([@bib3]), contained full length or fragmented proteins representing 4805 (91%) of the approximately 5400 protein-coding genes in the *P. falciparum* 3D7 genome, the remaining 3D7 genes being tiny (\<150 bp), challenging to clone or express or non-protein-coding genes. We found that a large proportion of the proteome was immunogenic in this study population, with personalized profiles detected by the protein microarray only moderately altered in response to PfSPZ Vaccine immunization. The moderate number of protected individuals (compared to volunteer infection studies in naïve populations), the heterogeneous immune fingerprint in the study population, and the potentially higher breadth of humoral immune response in the protected individuals highlight a complex picture to understand if humoral immune mechanisms lead to protection. Importantly, this study suggests that whole sporozoite vaccines predominantly boost pre-existing immunity of pre-exposed adults as a result of the natural imprinting of individual immune responses. Additionally, the moderate number of protected individuals seem to indicate that boosting pre-existing humoral response might not be sufficient to induce sterile protection against infection. If confirmed, these findings have implications for the role of such vaccines in endemic populations and thus prompts the need for studies to define appropriate target ages for immunization in settings of variable levels of pre-exposure.

The humoral immune response in the malaria pre-exposed study population was broad, with 2239 unique proteins considered reactive among the serum samples tested. This large number of immunoreactive targets is surprising, especially considering that the majority of targets are predicted to be localized intracellularly. This is in stark contrast to a recent panproteome-wide analysis of antibody-binding targets for *Streptococcus pneumoniae* proteins, which identified a more restricted set of a few hundred antigens and a clear association of immunoreactivity with cell surface localized, albeit functionally diverse, pneumococcal proteins ([@bib12]). The tendency of malaria antigens to span a more comprehensive set of cellular compartments is likely due to the increased complexity of the life cycle and chronicity of infection. In hepatocytes and erythrocytes, the biological processes of schizogony occur in parasitophorous vacuoles culminating in the destruction of the host cell and likely release of numerous abundant parasite proteins into the immune system ([@bib10]). We speculate this results in substantial immune responses to intracellular parasite proteins and a significant dedication of host immune resources that are potentially functionally irrelevant for control of infection. However, the potential for these proteins to initiate cascades of cellular responses that aid in parasite clearance should not be discarded and could be the focus of future high throughput cellular antigen discovery.

Volunteers had a personalized antibody profile at baseline, and this profile remained at the same level of individual complexity after repeated PfSPZ Vaccine inoculation. Most individuals had an extensive breadth of immune response, but the number of reactive antigens that the samples have in common was low (around 10%). This implies that the majority of reactive antigens are distinctly recognized at the individual level and confirming uniqueness of reactivity profiles across individuals, further suggesting clonal imprinting is occurring in malaria immunity. Such imprinting is consistent with antigen recognition being less variable in adult populations experiencing seasonal exposure compared to children ([@bib54]), with adults consistently either seropositive or seronegative for a specific antigen throughout the transmission season. Of note, antibody 'fingerprints' were recently reported in volunteers of a *S. pneumoniae* whole cell vaccine trial, whereby the overall antibody profile remained consistent even following multiple exposures to killed pneumococci ([@bib8]). A recent human cytomegalovirus (HCMV) vaccine study also found immune fingerprints where the vaccine boosted pre-existing immune responses implying a substantial effect of prior natural infection on vaccine induced immune responses for HCMV ([@bib4]). These examples along with a review on this possible mechanism of fingerprinting in nine pathogens, including Pf ([@bib57]), indicate that the phenomenon of 'original antigenic sin' which is known in the context of seasonal influenza vaccine goes beyond virus diseases. Our findings add to the increasing knowledge that -- across the taxa - the personalized immune and metabolic status and history of pathogen exposure may affect vaccine take and the potential to elicit high levels of protection in vaccinated populations ([@bib57]; [@bib56]; [@bib25]; [@bib4]).

A consistent picture is emerging that pre-exposure limits the magnitude of vaccine induced responses. The same immunization regimen as group 3 in our Tanzanian study was administered to Malian adults, with antibody responses to PfCSP 6 to 7-fold lower in Malians than in the Tanzanians ([@bib29]; [@bib50]). In contrast, higher anti-PfCSP levels were found following immunization in naïve U.S. vaccinees measured by same ELISA ([@bib20]; [@bib48]) as well as in unpublished proteome-wide analysis ([@bib8]), and in proteome-wide responses in European volunteers given chemo-attenuated sporozoites (PfSPZ-CVac) ([@bib38]). Studies of immunity induced after RTS,S vaccination have shown that anti-PfCSP titres are lower in Kenyan adults compared to naïve U.S. subjects, and a recent review on the immune response in RTS,S trials led to the hypothesis that pre-exposure might generate natural imprinting ([@bib58]). It is possible that, as with PfCSP antibodies, the magnitude of vaccine-induced responses to other parasite antigens were lower in Tanzanian vaccinees than their U.S. and E.U. counterparts ([@bib31]; [@bib43]).

Although we cannot conclude on correlates of protection from this study, we did find an extensive breadth of humoral immune response in protected individuals indicating an underlying immune profile of wider antigen recognition compared to non-protected. Breadth is known to be associated with reduced risk of malaria ([@bib42]; [@bib13]), and anti-malaria protection likely to be the sum of protective immunity across different antigens, a concept known as the threshold of immune response ([@bib17]). Several recent protein microarrays studies found a range of antigens that were associated with protection ([@bib11]; [@bib55]; [@bib15]). However, given the similar breadth profiles in the placebo group before and after placebo inoculation and the lack of any protected individuals in that group, it is more likely that the tendency for protected individuals to have higher antibody breadth represents a predisposition toward more effective PfSPZ Vaccine 'take', indicating that greater breadth prior to immunization may positively impact vaccination outcome. IgG specific to PfAMA1 and 3 variants of PfEMP1 were higher before CHMI in protected versus non-protected volunteers, but given the heterogeneous immune responses across volunteers, and the limited number of protected individuals, these antigens are not proposed as the mechanism for PfSPZ Vaccine induced immunity from this study. The three identified PfEMP1 antigens had higher levels in the protected individuals at baseline, indicating that higher levels of naturally primed, pre-existing PfEMP1 antibodies might be able to cross-react with other PfEMP1 proteins during CHMI.

We further found recognition of many more protein families in the protected group, including cell membrane proteins and numerous intracellular proteins. Protein families and functional categories uniquely identified in the protected group included the sporozoite protein SSP2/TRAP, a protein required for invasion of hepatocytes ([@bib39]). Interestingly, SSP2/TRAP antibodies were also detected in 26% of U.S. volunteers immunized with the same regimen of PfSPZ Vaccine as group 3 ([@bib20]). Additionally, the Rifin family, which are variant surface antigens exported to the infected erythrocyte surface and implicated in cytoadherence to the microvasculature and severe malaria ([@bib23]) and the Mauer's cleft, which is involved in trafficking variant surface antigens, including Rifins and PfEMP1s, to the infected erythrocyte surface ([@bib40]). While in many cases the magnitude of individual antibody responses was not significantly associated with protection, the analysis of protein families and functional categories can shed light on the types of antigens that may be targeted by a broad repertoire of antibodies conferring protection.

Given the small number of protected individual (n = 5) and the highly heterogeneous immune responses among the volunteers, results on potential association with protection of both individual antigens and breadth of humoral response in this study require further evaluation. Furthermore, four volunteers were protected in the highest immunization dose group (total of 1.35 million radiation attenuated sporozoites). Of particular note, the overall declining trend in antibody levels post-vaccination in both the lower dose and placebo groups was not evident in the higher dose group. Taken together, this indicates that vaccination with a higher dose induced a maintained immune status over time, and thus increasing doses in African pre-exposed volunteers may rescue vaccine immunogenicity and an active memory B cell pool. Larger trials will be required to confirm or reject that higher immunization doses lead to increased protection level in pre-exposed adults, with recent studies indicating a four-fold increase in immunization dose did not increase efficacy compared to a two-fold increase ([@bib30]). Our results pertain to adults only and, consistent with the theory that high malaria pre-exposure reduces vaccine induced immune response, a PfSPZ Vaccine may well induce higher immune responses in children of endemic areas compared to adults ([@bib30]). Further studies are needed to understand the level of protection a PfSPZ Vaccine in all age groups and consequently, the likely vaccine efficacy achieved in a mass vaccination strategy.

Both PfSPZ Vaccine induced humoral and cellular immune response have been observed and associated with protection in studies in naïve volunteers, but an association of either or both of these responses with protection in pre-exposed populations is unclear. Previously, the primary immune response to PfSPZ immunization was thought to be cellular based ([@bib19]) including that increased cellular immune response following PfSPZ immunization observed in malaria naïve individuals ([@bib28]). However, these responses measured in peripheral blood are not correlated with protection in pre-exposed immunized adults assessed by CHMI ([@bib29]; [@bib30]), likely due to protective cellular immune effector cells residing in the liver ([@bib28]). Furthermore, there is accumulating evidence that PfSPZ Vaccine induces or boosts humoral immunity to a surprisingly limited number of antigens in pre-exposed adults, with no correlation between anti-CSP antibody titres and CHMI protection ([@bib29]; [@bib30]; [@bib50]). This is despite previous reports that antibody responses are induced in US naïves ([@bib28]) and functional antibodies have been isolated from PfSPZ studies in Tanzania ([@bib53]; [@bib61]).

Although we undertook an unbiased analysis approach, the use of microarrays comes with limitations. Firstly, false-positive discovery adjustments for protein microarray analysis potentially underestimate the association of antigens, especially where differences are subtle and heterogeneity between the samples is high. Secondly, as for most protein microarray studies, sample sizes replicates were not preformed. Nevertheless, the immune fingerprint was similar for both samples before and after immunization for each volunteer. As the array experiment was designed to balance samples across experimental nuisance factors, such as study day and sample order, it is unlikely that variability observed between volunteers is attributable to non-reproducibility of the experiment. Thirdly, the proteins and protein fragments of the microarrays are produced in a cell-free environment resulting in several epitopes lacking post-translational modifications and potentially folded into unnatural conformations that therefore might not be bound by specific serum antibodies, resulting in false-negative results ([@bib16]). For this reason, this technology has been described as a 'rule-in' and not a 'rule-out' method ([@bib52]). Lastly, the paucity of information on the many functionally uncharacterized proteins present in the 5400 gene Pf proteome led to reliance on primarily *in silico* sequence prediction software to classify protein functional categories. Nevertheless, despite malaria-specific inaccuracies (details in Materials and methods), the DeepLoc analysis used in this study alongside gene ontology and protein family analysis provides valuable insight into overall distributions of the thousands of reactive antigens and those most recognized in protected individuals.

As information on the volunteers was limited, and as per design the study selected an apparently homogeneous population, it was impossible in the current analysis to examine associations of immune responses to different parasite or host factors. Thus, we cannot exclude associations between breadth of humoral immune responses, geographic location, immunogenetic background, transmission intensity, or other factors. Given the complexity and personalized immune response, we expect that much larger sample size, or a population meta-analysis, would be needed to identify any pattern of humoral response associated with host and parasite factors.

Further reduction and eventual elimination of malaria requires significant investment and research and development of new tools, including vaccines or other immune therapies ([@bib24]). Our proteome-wide analysis indicates the breadth of antibody repertoire to Pf malaria is extensive and highly variable between individuals who are pre-exposed. Our findings and those from other PfSPZ Vaccine trials in Africa are subject to confirmation with future research studies before any guidance can be made on the impact of pre-exposure on PfSPZ Vaccine efficacy and the implications for vaccination strategies. Nevertheless, we suggest, if these findings are confirmed, that the underlying, but difficult to assess, level of pre-exposure and resulting immune imprinting at the individual level may result in a more heterogeneous response to PfSPZ Vaccine. If personalized responses occur in pre-exposed individuals, then populations from different endemic regions cannot be considered homogeneous, and this will impact likely vaccination strategies. Similar to recent evidence for other pathogens ([@bib4]; [@bib8]; [@bib57]; [@bib56]), the potential impact of natural imprinting of humoral immune response in malaria deserves further investigation. Timing and duration of imprinting (infant age, childhood or throughout adulthood), as well as the role of co-infections and other yet to be identified host or environmental factors, are unknown. Without further fundamental studies, additional hurdles for future vaccine trials remain in regards to the validity of extrapolating vaccine outcomes from trials in naïve cohorts to pre-exposed populations and different age groups.

Materials and methods {#s4}
=====================

Ethic statement {#s4-1}
---------------

The study was approved by institutional review boards (IRBs) of the IHI (Ref. No. IHI/IRB/No:02--2014), the National Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol.IX/1691), the Ethikkommission Nordwest-und Zentralschweiz, Basel, Switzerland (reference number 261/13), and by the Tanzania Food and Drug Authority (Ref. No.TFDA 13/CTR/0003); registered at Clinical [Trials.gov](http://Trials.gov) (NCT02132299); and conducted under U.S. FDA IND 14826.

Study design of the original trial {#s4-2}
----------------------------------

The design and outcome of the clinical study is described in detail in [@bib29]. Briefly, volunteers were immunized five times with a lower (1.35 × 10^5^) or a higher dose (2.7 × 10^5^) of PfSPZ Vaccine by direct venous inoculation (DVI) at 4 week intervals for the first four vaccinations followed by a last booster with PfSPZ Vaccine after 8 weeks. After immunization, volunteers underwent CHMI either 3 weeks after last immunization, 24 weeks after last immunization, or both using 3200 non-attenuated aseptic, purified, cryopreserved, infectious PfSPZ of PfSPZ Challenge administered by DVI. Serum samples for microarray analysis were collected at baseline (before immunization) and 2 weeks after last immunization in the individuals who underwent CHMI at 3 weeks after last immunization ([Figure 1](#fig1){ref-type="fig"}).

The 36 volunteers were healthy, adult males between 18--35 years old, with no parasitemia at the start of the study (measured by TBS and antibodies to PfEXP1 by ELISA), no history of malaria episodes over the last 5 years, and no parasitemia before CHMI (measured by TBS and qPCR) ([@bib29]). They were all students in Dar Es Salaam at the time of the study, however home town or travel history was not specified; thus, history of geographic exposure is not known.

Protein array chip design {#s4-3}
-------------------------

The protein microarray used in this study was produced by Antigen Discovery, Inc (ADI) and encompasses 7455 full-length or fragmented Pf proteins representing 4805 protein-coding genes and covering 91% of the proteome ([@bib38]). As previously described ([@bib21]) proteins were expressed from a library of Pf partial or complete open reading frames (ORFs) cloned into a T7 expression vector pXI using an in vitro transcription and translation (IVTT) system, the *Escherichia coli* cell-free Rapid Translation System (RTS) kit (5 Prime). This library was created via an *in-vivo* recombination cloning process with PCR-amplified Pf ORFs, and a complementary linearized expressed vector transformed into chemically competent *E. coli* was amplified by PCR and cloned into pXI vector using a high-throughput PCR recombination cloning method ([@bib14]). Each expressed protein includes a 5′ polyhistidine (HIS) epitope and 3′ haemagglutinin (HA) epitope. Proteins were expressed according to manufacturer's instructions and then translated proteins were printed onto nitrocellulose-coated glass AVID slides (Grace Bio-Labs) using an Omni Grid Accent robotic microarray printer (Digilabs, Inc). Quality checks of the microarray chip printing and protein expression were performed by probing random slides with anti-HIS and anti-HA monoclonal antibodies with fluorescent labelling. In addition to the 7,455 Pf peptide fragments, each microarray chip contained 302 IgG positive control spots as an assay control and 192 in vitro Transcription and Translation (IVTT) control spots (IVTT reactions with no Pf ORFs) as a normalization factor. All the spotted proteins were printed in three replicated pads per slide to accommodate one sample per pad. The experiment included two chips that made up the full proteome microarray, and samples were probed on each chip. Due to cost constraints, we did not replicate the experiment. Prior to probing samples, a balanced array experimental design was generated to mitigate nuisance factors, including pad position and day that sample was assayed, against sample grouping factors such as time point, dosing group and protection status. Sample balancing factors were provided as blinded, coded variables by Sanaria, Inc to ADI and unblinded following data acquisition.

Sample probing {#s4-4}
--------------

Sample probing has been previously described elsewhere ([@bib7]; [@bib38]). Briefly, serum samples were diluted 1:100 in a 3 mg ml−1 *E. coli* lysate solution in protein arraying buffer (Maine Manufacturing) and incubated at room temperature for 30 min. Chips were rehydrated in blocking buffer for 30 min. Blocking buffer was removed, and chips were probed with serum samples by incubating in sealed, fitted slide chambers to ensure no cross-contamination of sample between pads. Chips were incubated overnight at 4°C with agitation. Chips were washed five times with TBS-0.05% Tween 20, followed by incubation with biotin-conjugated goat anti-human IgG (Jackson ImmunoResearch) diluted 1:200 in blocking buffer at room temperature. Chips were washed three times with TBS-0.05% Tween 20, followed by incubation with streptavidin-conjugated SureLight P-3 (Columbia Biosciences) at room temperature protected from light. Chips were washed three times with TBS-0.05% Tween 20, three times with TBS, and once with water. Chips were air dried by centrifugation at 1000 g for 4 min and scanned on a GenePix 4300A High-Resolution microarray scanner (Molecular Devices), and spot and background intensities were measured using an annotated grid file (.GAL). Data adjusted for local background by subtraction were exported to Microsoft Excel as CSV files and subsequently imported into R ([@bib44]) where all subsequent data processing occured.

Protein array data processing {#s4-5}
-----------------------------

Signal intensities were transformed by base two logarithm, and the median of IVTT control spots for each sample was subtracted from the sample-specific IVTT Pf antigen signals, a method that has been used previously in protein microarray analysis ([@bib38]; [@bib21]). A seropositive threshold was defined as two times IVTT control signals, or 1.0 on the log~2~ scale. A value of 0.0 +/- 1 represents signal intensities that are equivalent to the background. Values below −2, representing less than 0.25 times the median IVTT control signals were adjusted to −2. This affected 1639 of the 685,860 signals included in the complete dataset and 42 of the 257,968 signals included in the set of reactive antigens. Reactive antigens were defined as proteins that were seropositive in at least 10% of the study population at one or more time points. High level group reactivity was defined as 80% seropositivity to one probe in vaccinees who received either the lower (group 2) or higher (group 3) doses of PfSPZ Vaccine.

Analysis {#s4-6}
--------

To visualize the high dimensional dataset of the microarray spots and understand potential patterns or clustering of the samples, t-SNE analysis ([@bib36]) was used with a perplexity value of 30 and with 10,000 iterations. The t-SNE algorithm was applied the 92 samples of the entire dataset of the 2804 log~2~-transformed signal intensities or for the subset of 441 reactive proteins fragments predicted to be expressed at the sporozoite stage ([@bib22]). The breadth of immune response for each individual was defined as the total number of positive reactive antigens for each serum draw. Breadth data were identified as over-dispersed after observing that the variance was greater than the means. Therefore, breadth between different groups was compared using negative binomial regression. The frequencies of reactive antigens summed into subcellular localization categories for each group were tested using 2-propotions Z-test and p-values adjusted using the BH method. Gene Ontology (GO) annotation for each protein was retrieved from [PlasmoDB.org](http://PlasmoDB.org). Protein families were queried using amino acid sequences for each protein using the Pfam database ([@bib18]). Fisher's exact tests were used to assess reactivity of each GO category of Pfam functional group, followed by p-value adjustment using the BH method.

The mean reactivity of each antigen per study group (control, group 2 and group 3) 2 weeks after immunization was compared with baseline levels (pre-immunization), using the paired t-test and by adjusting for false discovery rates (FDR) with the Benjamini-Hochberg method (BH) ([@bib5]). One individual in group 2 who received 4 instead of 5 doses of immunization was excluded from this analysis. 'Delta' was defined as the fold change in antibody reactivity for each antigen before and after immunization. The average delta was compared between the vaccinated and the control groups using the unpaired t-test, and the resulting p-values were adjusted with the BH method. Because of the heteroscedastic nature of the normalized log~2~ signal intensities ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}) we preferred the ordinary t-test over the empirical Bayes test (eBayes) ([@bib51]), which is sometimes used to compare signal intensities in microarray experiments. Due to the large number of positive probe signals and changes between time points, the eBayes could estimate a prior distribution that is over-dispersed relative to the paired t-test resulting in reduced power to detect changes in outlier responses, whereas eBayes may be more suitable for full proteome microarray studies with more restricted immunoreactivity profiles ([@bib8]).

Common antigens to a group were defined as antigen which are reactive in at least 60%, 80% or 100% of the samples of the group and differences in frequencies of commonly recognized antigens between groups were assessed with a 2-sample test for equality of proportions with continuity correction. To account for the large difference in sample sizes between the protected (n = 5) and unprotected (n = 33) groups, bootstrap samples with n = 5 samples in each group were repeatedly drawn (repeated 1000 times), with replacement.

Amino acid sequences for each protein were queried using the DeepLoc online program to predict subcellular localization of each protein ([@bib1]). Algorithms for prediction of subcellular localization of eukaryotic parasite proteins have not been trained like they have for Gram negative and positive bacteria, mammalian, plant and fungal cells, and DeepLoc program was trained to the latest UniProt dataset that reported higher accuracy using primary sequence input and deep neural networks over methods reliant on homology ([@bib1]). No subcellular localization categories exist in these algorithms for the specialized organelles of malaria, such as the rhoptries and micronemes, which exocytose internal parasite proteins to the surface of the parasite membrane, parasitophorous vacuoles or host cell cytoplasm and membrane. Thus, many proteins such as the majority of PfEMP1 variants were misclassified as localized to the endoplasmic reticulum, golgi apparatus, cytoplasm or nucleus. The parasite apicoplast is also absent from these algorithms. Training to these organelles can only be done with a substantial database of sequences with which to train models, which is currently in limited supply for eukaryotic parasites.
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###### Gene and protein families present in the protected versus non protected groups.

This table lists Pfam protein family prediction ([@bib18]), and gene ontology prediction available on [Plasmodb.org](http://plasmodb.org/) ([@bib27]) and identified protein characteristics and distinct functional categories which were identified as being reactive in at least 80% of the protected or non protected group before and after immunization. Reactive proteins were associated to each group using the Fisher's exact test, and p value correct using the Benjamini-Hochberg method (BH) ([@bib5]). Pfam and GO description were found in <https://www.ebi.ac.uk/QuickGO/> and <https://biocyc.org/> and <https://www.ebi.ac.uk/QuickGO/> and <https://biocyc.org/>, respectively. See also [Source datas 1](#sdata1){ref-type="supplementary-material"}--[4](#sdata4){ref-type="supplementary-material"}.
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All data analyzed during this study are included in the manuscript and supporting files, or cited accordingly when published elsewhere.
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**Acceptance summary:**

Attenuated *Plasmodium falciparum* sporozoites (PfSPZ) represent one of the potential whole organism vaccines against malaria. In this study conducted in Tanzania, adult males were immunized with PfSPZ and protection against malaria was assessed by exposure to infectious Pf sporozoites. Antibody responses measured prior and after vaccination suggest that the PfSPZ induced but a moderately increased response and that the pre-existing immune responses might have reduced vaccine induced reactivity.

**Decision letter after peer review:**

Thank you for sending your article entitled \"Proteome-wide humoral immunity of immunized adult malaria pre-exposed volunteers reveals personalized antibody profiles\" for peer review at *eLife*. Your article has been evaluated by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Dominique Soldati-Favre as the Senior Editor.

On the basis of the reviews provided by the three reviewers, there is a consensus regarding critical issues that require your attention. It appears that for the exclusion criteria, you have relied on serological assays for determinations of previous exposure to malaria. A more sensitive assay, such as PCR, should be performed to exclude any possibility of a prior malaria at pre-vaccination. In addition, re-analysis of results shown in Figures 1-5 is warranted for transparency and clarity as well as for the conclusions that antibodies to AMA-1 and PfEMP1 are the key mediators of protection induced by PfSPZ immunization. In view of the possible modifications of your conclusions, please revise the Discussion section to reflect these changes.

Reviewer 1:

Materials and methods: It appears that subjects were excluded on the basis of serological test for anti PfEXP-1 antibodies. This may not have been sufficiently sensitive assay. Was PCR-based assay done to check for parasitemia? Please address this important issue as the presence of asexual parasites pre-vaccination could have influenced the baseline antibody responses recorded, as well as the participants\' anti-vaccine responses.

Results: The text associated with results shown in Figure 3 is not informative, hence detailed and clearer explanation of panels C and D needs to be provided. Please revise the legends to remove errors. Legend for panel E is missing. Amongst the proteins reported to be recognized significantly higher post-immunization in the protected group vs. the non-protected group is AMA1 (subsection "Association with protection", last paragraph). The authors need to better explain how this outcome reflects the listings in Figure 7---source data 1 in which AMA1 is documented as at the top of the list (recognized by 24/33 individuals?) of proteins \'Increased in non-Protected\' as well as in the \'Group 3 increased in non-Protected\' list? Was the documented increase in response to AMA1 in the protected group simply greater than that observed in the non-protected group? The authors need to clarify what appears to be an anomaly in the data provided.

Discussion: The issue of pre-existing antibody responses (immune imprinting) is of potential importance in the clinical development of such a vaccine, in that such testing necessarily involves trials in older (African) age groups. It may possibly be less of an issue in African children who are one of the stated target groups for the vaccine. On the other hand the authors have previously stated (Jongo et al., 2019) that the protection conferred by their vaccine is thought to depend primarily on induction of cell-mediated immunological responses. That being the case, it could be argued that the presence or absence of pre-existing antibody responses -- that themselves are inevitably less well-developed in young African children -- becomes a comparatively minor consideration in the context of implementation in a mass vaccination programme designed to halt transmission of the parasite. Or do the authors now think -- on the basis of the results presented here -- that antibody responses may indeed make a contribution to the protection induced by their vaccine?

From a general standpoint, the interpretation of the study findings as a whole perhaps merits some further thought. It seems somewhat surprising that the administration of a total of at least 675 000 live radiation-attenuated sporozoites is (i) required to induce sterile immunity, (ii) necessary to register some measurable change in anti-parasite antibody responses (i.e. an increase in % \'high magnitude\' antigens recognized by protected individuals), and (iii) associated with a significant change, post-immunization and pre-challenge, with antibody responses to just 4 different individual proteins in the individuals shown to have sterile protection. Do these findings simply underline the authors\' own stated hypothesis, namely that protection induced by the PfSPZ vaccine is associated primarily with a cellular rather than a humoral response? The results certainly do seem to indicate that the large numbers of irradiated sporozoites administered as a vaccine that terminate their development in the liver appear not to have the capacity to substantially affect a majority of the anti-parasite antibody responses measured in the study. The absence of statistically significant differences following appropriate adjustment attests to that.

In the context of the authors\' stated concept of using PfSPZ Vaccine in mass vaccination programmes, the comparatively poor efficacy against homologous challenge infection in African adults shown by the study is not encouraging for such a vaccine if the intention is to deploy it at a broad community-wide scale. The authors should perhaps consider discussing further how they think modifications incorporating \'the role of vaccine dosing and regimen on vaccine-induced immunity\' might contribute to improving the overall performance of the vaccine in older African age-groups. If homologous protection is already rather low, what are the implications for the levels of heterologous protection in the same group of individuals? Discussion of these aspects should also take into account their published findings (Jongo et al., 2019) indicating comparatively poor T cell-mediated responses in PfSPZ-vaccinated Tanzanian adults.

Reviewer 2:

Introduction: The Introduction clearly sets out the current state of development of RTS,S and Spz. The section on immune correlates would benefit from more clearly separating mechanistic studies in mice from human challenge work where in vivo correlates might be statistically inferred. Both are valuable and both have drawbacks. Before the last paragraph on the role of microarrays it would be useful to summarize the foregoing review of potential correlates -- e.g. to state that lead candidate correlates/mechanisms appear to be a b and c or that the field continues to be wide open with no consistent findings. The Introduction would also benefit from a shorter version.

Materials and methods: Can the authors comment about the validation of the peptide structures? How many are properly folded/ have correct confirmation etc.?

Results: Figure 2. The decline in reactivity post vaccination looks striking in the control group and in group 2. Why is the volcano plot clearly asymmetrical? Is there a batch effect?

Likewise when breadth is said to increase in 6/18in group 2 this means it decreases in 12/18 and this seems to be borderline significant (p=0.03).

Figure 3. This is the first time protected vs. non-protected result appears in the analysis. Why not from the start and why not volcano plots as shown in Figure 1 for protected vs. non-protected?

Categorizing antigens as low/middle/high then showing numbers of antigens in box plots seems a very counter-intuitive way of presenting the results for multi-dimensional data, much less familiar than volcano plots. Can this be justified?

Figure 4. I do not understand how the t-SNE plots further probe the finding of breadth not increasing. This is claimed as the objective, but the two ideas are not further linked in the description of results.

I have questions on the sentence \"The number of antigen features recognized in at least 80% of the protected group (4 out of 5 individuals) was higher than in the unprotected group (27 out of 33 individuals) 2 weeks after 281 last immunization (383 reactive antigens in the protected group versus 58 in the unprotected\".

Why pick that 80% to test in comparison with the unprotected group? There is a very confident p value to get out of a comparison of 4 individuals with another group (2\*10\^-16). I cannot completely follow the description of the analysis, but I doubt that such a p value can be gained from a well justified significance test in such a small group. A more transparent and simple analysis is strongly suggested. A volcano plot showing distributions of p values and effect sizes would be better, and this has been missed out in Figures 1 and 2.

Antibodies to AMA1 are the \"second most significant increases\" but text doesn\'t cover details for the most significant (i.e. PfEMP1). The unadjusted p value is 0.02 and 0.0002 but adjusted p values are 0.42 and 0.26. This does not seem to fit with the previous text, and I feel the whole area of significance testing here needs more clarity.

Figure 5. Volcano plots are back, but again they are not showing a comparison with protected vs. non-protected but rather pre/post divided for protected vs. non-protected. The sets above of reactive antigens pre (a) and post (b) seem to imply that as much difference may have been in the pre-vaccination reactivity as in the post. Can this be clarified?

Taken together I do not accept the key conclusion in the Abstract that antibodies to PfEMP1 and AMA1 were the key mediators of protection here. I would also be puzzled from an a priori perspective as sub-unit vaccines based on AMA1 have not been highly protective whereas in contrast PfSPZ has, and it is hard to accept this is primarily due to AMA1 responses.

Reviewer 3:

Building on antibody focused assessments completed during the course of PfSPZ Vaccine studies in Tanzania, Camponovo et al. seek to describe changes in humoral immune responses pre/post PfSPZ Vaccine (2 different doses) or placebo via Pf protein microarrays. They present results that highlight the diversity of pre-existing responses in presumed malaria exposed population and lack of significant clear changes in those who are vaccinated; though some fold changes in AMA-1 and PfEMP1 were seen in those who were protected from homologous CHMI.

Results: This section seems a bit unclear in its focus and explanation. Based on the Introduction, I was expecting to see results showing change in responses trying to target vaccine specific responses and impact pre-existing immunity may have on these responses. Thus I was expecting clear figures with defining degree of pre-existing exposure (and clear explanation and rationale on how this is defined; was this only defined by array responses or was there another measure to attempt to capture an individual\'s pre-existing exposure -- clinical or immunological; have these definitions been validated prior) and how PfSPZ vaccination changed this response compared to similar controls, within an individual, and even though the numbers are small for those protected, if that change in IgG profile(s) can be seen in protected versus non-protected. I believe Figure 3 panels are attempting to do this but find it hard to track clearly the story being told and the relevance on a bigger scale as it\'s discussed later on in the paper.

Discussion: This section goes into the individual complexity of the array signatures even prior to vaccination, but would be interested to see if there was further analysis into age, prior residence, occupation, known malaria exposure, etc impacted this initial signature rather than assuming all male participants coming into the study were of equal prior malaria exposure. The interesting impact from this research, I believe, is this assessment of possible pre-vaccination imprinting and what can we learn from this to improve vaccine strategies, including PfSPZ vaccine. I believe more should be focused on this given the results presented really had no clear post vaccination signature seen and protected vs. unprotected numbers were extremely small for wider conclusions on possible markers of protection. Exploring how different individuals with perhaps very similar exposure backgrounds come into a vaccine trial and if a vaccine can alter this pre-existing baseline to promote benefit is crucial to vaccine success and worth focusing more clearly on.

10.7554/eLife.53080.sa2

Author response

> On the basis of the reviews provided by the three reviewers, there is a consensus regarding critical issues that require your attention. It appears that for the exclusion criteria, you have relied on serological assays for determinations of previous exposure to malaria. A more sensitive assay, such as PCR, should be performed to exclude any possibility of a prior malaria at pre-vaccination. In addition, re-analyses of results shown in Figures 1-5 is warranted for transparency and clarity as well as for the conclusions that antibodies to AMA-1 and PfEMP1 are the key mediators of protection induced by PfSPZ immunization. In view of the possible modifications of your conclusions, please revise the Discussion section to reflect these changes.
>
> Reviewer 1:
>
> Materials and methods: It appears that subjects were excluded on the basis of serological test for anti PfEXP-1 antibodies. This may not have been sufficiently sensitive assay. Was PCR-based assay done to check for parasitemia? Please address this important issues as the presence of asexual parasites pre-vaccination could have influenced the baseline antibody responses recorded, as well as the participants\' anti-vaccine responses.

We thank reviewer 1 for their thoughtful and helpful comments. All points have influenced our updated manuscript.

We are confident that all volunteers were parasite free both at the start of the study and before CHMI. At enrolment, all volunteers were screened by thick blood smear (TBS) for malaria and only volunteers that tested negative were included (Supplementary Table 3 of Jongo et al., 2018). Volunteers were screened before CHMI (that is 21 days after fifth vaccination) by TBS and qPCR for malaria and all subjects were found to be negative using both detection methods (Jongo et al., 2018). The fact that none of the volunteers was detected during the vaccination period by TBS as malaria positive, that none of the volunteers developed malaria during the vaccination period, and that all volunteers were malaria negative (as per qPCR) before CHMI, strongly suggests that these volunteers were negative for malaria at enrolment. The details of exclusion criteria can be found in the clinical trial paper (Jongo et al., 2018), but the reviewer's comment made it clear that this aspect is critical for the interpretation of our results and we have now added the following specifications in the manuscript:

In Results, section on Study volunteers and serum sampling:

*"*All volunteers included in the study had no parasitemia at the start of the study (measured by malaria thick blood smears (TBS)) and no parasitemia before CHMI (measured by TBS and the more sensitive qPCR) (Jongo et al., 2018). Additional exclusion criteria included history of malaria in the previous 5 years or antibodies to PfEXP1 by ELISA above a threshold level (Jongo et al., 2018) associated with recent infection by CHMI (Shekalaghe et al., 2014)."

And in the Materials and methods section "Study design of the original trial":

"The 36 volunteers were healthy, adult males between 18-35 years old, with no parasitemia at the start of the study (measured by TBS and antibodies to PfEXP1 by ELISA), no history of malaria episodes over the last 5 years, and no parasitemia before CHMI (measured by TBS and qPCR) (Jongo et al., 2018). They were all students in Dar Es Salaam at the time of the study, however home town or travel history was not specified; thus, history of geographic exposure is not known."

> Results: The text associated with results shown in Figure 3 is not informative, hence detailed and clearer explanation of panels C and D needs to be provided. Please revise the legends to remove errors. Legend for panel E is missing.

Thank you, this is a very helpful comment as we realized that by modifying this figure and by restructuring the Results section we could improve the clarity of our Results section.

We have now changed the plots as follows.

i\) Originally Figure 3A-B is now a separate figure (Figure 3B-C) and we also included breadth before immunization for each individual (Figure 3A);

ii\) original Figure 3D-E on the magnitude of response have been removed, and

iii\) original Figure 3C is now a separate figure (Figure 6).

We agree that the plot on magnitudes provided only weak additional information compared to plots of breadth of response, thus for clarity, we have removed these plots.

> Amongst the proteins reported to be recognized significantly higher post-immunization in the protected group vs. the non-protected group is AMA1 (section "Association with protection", last paragraph). The authors need to better explain how this outcome reflects the listings in Figure 7---source data 2 in which AMA1 is documented as at the top of the list (recognized by 24/33 individuals?) of proteins \'Increased in non-Protected\' as well as in the \'Group 3 increased in non-Protected\' list? Was the documented increase in response to AMA1 in the protected group simply greater than that observed in the non-protected group? The authors need to clarify what appears to be an anomaly in the data provided.

We thank reviewer 1 for this comment, which helped us to improve the clarity of our analysis. The Results section has been restructured in response to the overall comments of the reviewers. This restructure includes separating the Venn diagrams showing the commonly recognized antigens in 80% of the samples of a given group (updated Figure 7), and the volcano plots showing the mean difference in signal intensity between the protected and unprotected groups or the two sample time points (updated Figure 5). Separating those results and adding more details on these two sets of analysis, hopefully, clarifies the different outputs displayed in the Figure 7---source data 1 and the volcano plots.

Figure 7---source data 1 lists antigens that were reactive or where reactivity increased from baseline to after immunization, in at least 50% of the samples for a given group. The list indeed shows that 2 weeks after immunization PfAMA1 signals had increased compared to baseline levels in 4 out of 5 protected volunteers (80%) and in 24 out of 33 non-protected volunteers (72%). These lists do not indicate the magnitude of the increase or if the mean signal level before versus after immunization can be considered significantly different. This analysis was used to examine the number of commonly reactive antigens per group rather than the analysis of the reactivity levels of the individual antigens. The latter was performed by comparing the mean signals between different groups, evaluated using the student test statistics, and displayed through volcano plots. These volcano plots showed that the mean antigen reactivity for four proteins, including PfAMA1, was higher in the protected group compared to the non-protected group 2 weeks after immunization (Figure 5B in the new version of the manuscript). This is referred in the reviewer's comment "Amongst the proteins reported to be recognized significantly higher post-immunization in the protected group vs. the non-protected group is PfAMA1."

In the protected group, no antigens significantly increased in reactivity after immunization compared to baseline (Figure 5C). We did not look at the mean increase of PfAMA1 and other antigens in the unprotected group between before and after immunization, but given the number of protected (n=5) and unprotected (n=33) it would likely be similar to Figure 4B-C which shows the increase from baseline in all immunized samples (regardless protection) of group 2 and group 3. Although the mean log fold change of the signal of PfAMA1 was 0.3 in group 2 and 0.6 in group 3 (which are the second and third highest fold change in group 2 and group 3, respectively), it did not meet the significance threshold, and PfAMA1 is not highlighted in the plots. Delta, the differential increase before to after immunization, was not significantly higher in the protected compared to the unprotected group (Figure 5---figure supplement 2).

We hope that the restructuring of the Results as a whole makes it easier to follow the analysis, including clarifying this comment. Specifically, we included the following sentences:

At the beginning of the third paragraph of the section "Moderate increase in antigen recognition following immunization with PfSPZ Vaccine":

"To identify potential differences in vaccine induced immunogenicity between protected and unprotected individuals, we compared the difference in the mean immunoreactivity (i.e. signal intensity) for each antigen at baseline and 2 weeks after immunization between protected (n=5) and unprotected (n=33) volunteers, and the difference in the mean immunogenicity of each antigen between baseline and post immunization time points in the protected group (Figure 5)";

At the end of the 3rd paragraph of the section "Moderate increase in antigen recognition following immunization with PfSPZ Vaccine":

"No antigen showed an increase in reactivity (delta) significantly higher in the protected group (Figure 5---figure supplement 2)."

At the beginning of the second paragraph of the section "Breadth of humoral immune response in protected individuals":

"Finally, in order to identify antibodies consistently present in the samples of the protected individuals, we defined common antigens to a group as antigens which are reactive in at least 80% of the samples for each of the groups (i.e. considering the signal intensity of a given antigen as a binary outcome, either reactive or non-reactive)."

> Discussion: The issue of pre-existing antibody responses (immune imprinting) is of potential importance in the clinical development of such a vaccine, in that such testing necessarily involves trials in older (African) age groups. It may possibly be less of an issue in African children who are one of the stated target groups for the vaccine. On the other hand the authors have previously stated (Jongo et al., 2019) that the protection conferred by their vaccine is thought to depend primarily on induction of cell-mediated immunological responses. That being the case, it could be argued that the presence or absence of pre-existing antibody responses -- that themselves are inevitably less well-developed in young African children -- becomes a comparatively minor consideration in the context of implementation in a mass vaccination programme designed to halt transmission of the parasite. Or do the authors now think -- on the basis of the results presented here -- that antibody responses may indeed make a contribution to the protection induced by their vaccine?

We thank the reviewer for that comment. We believe that to date, it remains unclear what immune mechanisms lead to protection following PfSPZ vaccine immunization, especially in pre-exposed population. To date cellular immune responses are thought to play a major role in protection, although cells located in the liver have not been measured in clinical studies and thus effective cellular immune response in the liver remains unclear. On the humoral side, functional antibodies have been isolated in both naïve and pre-exposed populations. Due to the small sample size of protected individuals, and the heterogeneous responses observed in this study we don't think we can make strong statements on the role of humoral immune response for acquiring protection, but we think it should not be ruled out.

We have edited the Discussion section. In particular, to clarify current knowledge of cellular and humoral immune response, we added a ninth paragraph:

"Both PfSPZ Vaccine induced humoral and cellular immune response have been observed and associated with protection in studies in naïve volunteers, but an association of either or both of these responses to protection in pre-exposed populations is unclear. \[...\] This is despite previous reports that antibody responses are induced in in naives (Ishizuka et al., 2016) and functional antibodies have been isolated from PfSPZ studies in Tanzania (Tan et al., 2018, Zenklusen et al., 2018)."

> From a general standpoint, the interpretation of the study findings as a whole perhaps merits some further thought. It seems somewhat surprising that the administration of a total of at least 675 000 live radiation-attenuated sporozoites is (i) required to induce sterile immunity, (ii) necessary to register some measurable change in anti-parasite antibody responses (i.e. an increase in % \'high magnitude\' antigens recognized by protected individuals), and (iii) associated with a significant change, post-immunization and pre-challenge, with antibody responses to just 4 different individual proteins in the individuals shown to have sterile protection. Do these findings simply underline the authors\' own stated hypothesis, namely that protection induced by the PfSPZ vaccine is associated primarily with a cellular rather than a humoral response? The results certainly do seem to indicate that the large numbers of irradiated sporozoites administered as a vaccine that terminate their development in the liver appear not to have the capacity to substantially affect a majority of the anti-parasite antibody responses measured in the study. The absence of statistically significant differences following appropriate adjustment attests to that.

We thank the reviewer for this comment. We have completed major edits on the Discussion, including additional literature, to emphasize the primary outcome of this analysis, namely the effect of the natural imprinting on vaccine induced humoral immune response in pre-exposed adults. Whether or not humoral, cellular, or both immune responses are the main drivers of vaccine induced sterile immunity remains unknown, and hopefully, this is clarified with the additional section in the Discussion. We agree with the last comment of reviewer \#2, but we suggest that the moderate change in the antibody immune response profile is due to natural imprinting, which is the main focus of the Discussion, mainly in the third and fourth paragraph.

We added a paragraph on the current knowledge about humoral and cellular immune response induced by PfSPZ Vaccine (see previous comment), and in the fourth paragraph of the Discussion we highlight that the vaccine induced humoral immune response are very different in malaria naïve and malaria exposed individuals, with naïve volunteers finding to have much higher PfSPZ Vaccine induced antibody levels. In addition, to highlight the reviewer's comments (i), (ii) and (iii) in our Discussion, we have now added the following paragraph:

"Furthermore, 4 volunteers were protected in the highest immunization dose group (total of 1.35 million radiation attenuated sporozoites). \[...\] Further, studies are needed to understand the level of protection a PfSPZ Vaccine in all age groups and consequently, the likely vaccine efficacy achieved in a mass vaccination strategy."

> In the context of the authors\' stated concept of using PfSPZ Vaccine in mass vaccination programmes, the comparatively poor efficacy against homologous challenge infection in African adults shown by the study is not encouraging for such a vaccine if the intention is to deploy it at a broad community-wide scale. The authors should perhaps consider discussing further how they think modifications incorporating \'the role of vaccine dosing and regimen on vaccine-induced immunity\' might contribute to improving the overall performance of the vaccine in older African age-groups. If homologous protection is already rather low, what are the implications for the levels of heterologous protection in the same group of individuals? Discussion of these aspects should also take into account their published findings (Jongo et al., 2019) indicating comparatively poor T cell-mediated responses in PfSPZ-vaccinated Tanzanian adults.

We agree with the reviewer's comment that we have not emphasized strongly enough the implications of the findings for mass vaccination strategies. We don't think our findings are sufficient to make recommendation either way on the use of such a vaccine in mass vaccination strategies, or suggest potential modifications that should be made. However, we suggest based on our findings that natural imprinting will be an additional challenge for vaccination in adults from African populations, and that further investigation is required to understand the direct implications. We hope that the significant edits to our Discussion better convey this message. In particular, to the reviewer's comments, we have modified our concluding paragraph as follows:

*"*Our proteome-wide analysis indicates the breadth of antibody repertoire to Pf malaria is extensive and highly variable between individuals who are pre-exposed. \[...\] Without further fundamental studies, additional hurdles for future vaccine trials remain in regards to the validity of extrapolating vaccine outcomes from trials in naïve cohorts to pre-exposed populations and different age groups."

> Reviewer 2:
>
> Introduction: The Introduction clearly sets out the current state of development of RTS,S and Spz. The section on immune correlates would benefit from more clearly separating mechanistic studies in mice from human challenge work where in vivo correlates might be statistically inferred. Both are valuable and both have drawbacks. Before the last paragraph on the role of microarrays it would be useful to summarize the foregoing review of potential correlates -- e.g. to state that lead candidate correlates/mechanisms appear to be a b and c or that the field continues to be wide open with no consistent findings. The Introduction would also benefit from a shorter version.

We thank reviewer \#2 for their thoughtful and helpful comments. These are constructive and helpful comments that provided significant inputs for improving the Introduction. With have shortened and restructured the Introduction for more clarity. We have separated in vitro from in vivo studies of protection correlates, as well as more clearly identified studies in mice, non-human primates, naïve humans and pre-exposed humans, as we agree that this would be easier to read. Our review of current knowledge of PfSPZ Vaccine induce immune response is now described in the fourth paragraph (cellular immune response with first studies in mice, followed by studies malaria naïve, and malaria exposed volunteers), fifth paragraph (humoral immune response), and sixth paragraph (studies on the functional role of antibodies).

To address the last comment, we have included the following sentence in the last paragraph of the Introduction to highlight that mechanisms leading to protection remain an open question:

"The main in-vitro, animal, and human studies described above suggest that both cellular immune response and antibody mediated immune response play a role in inducing protection. However, a complete understanding of the mechanisms of vaccine-induced protection against malaria infection, and its interplay with pre-built natural immune response in exposed populations, remains unknown".

> Materials and methods: Can the authors comment about the validation of the peptide structures? How many are properly folded/have correct confirmation etc.?

We thank the reviewer for pointing out this missing information in our Materials and methods. In the Discussion, we already highlighted the limitation of the protein microarray to ensure properly folded epitopes, and thus this technology being referred to as a "rule in" and not "rule out" method. But we have now added more specification in the Materials and methods:

"As previously described (Felgner et al., 2013) proteins were expressed from a library of Pf partial or complete open reading frames (ORFs) cloned into a T7 expression vector pXI using an in vitro transcription and translation (IVTT) system, the *Escherichia coli* cell-free Rapid Translation System (RTS) kit (5 Prime). \[...\] Quality checks of the microarray chip printing and protein expression were performed by probing random slides with anti-HIS and anti-HA monoclonal antibodies with fluorescent labelling."

> Results: Figure 2. The decline in reactivity post vaccination looks striking in the control group and in group 2. Why is the volcano plot clearly asymmetrical? Is there a batch effect?
>
> Likewise when breadth is said to increase in 6/18in group 2 this means it decreases in 12/18 and this seems to be borderline significant (p=0.03).

We thank the reviewer for this comment. The overall decline in reactivity after immunization was surprising to us. We are confident that this is not due to experimental biases, as samples were balanced for group and time point factors across technical microarray factors using a block randomization design. Sample balancing factors were provided as blinded, coded variables by Sanaria, Inc to ADI and unblinded following data acquisition. This is specified in the Materials and methods section "Protein array chip design", and highlighted this in the Results:

"During the period before and after vaccination, antibody breadth declined in many individuals in the control and immunized groups (note that samples were balanced for group and time point factors across technical microarray factors using a block randomization design, see Materials and methods)".

We agree that the breadth of responses tends to decrease in the control group, and in group 2, and we measured the difference in breadth before and after vaccination with the inverted beta-binomial test for paired count data which resulted in an estimated fold change of -1.23, -1.16 and 1.03, and a p-value of 0.24, 0.03 and 0.43 for control, group 2, and group 3 respectively. Indeed, the fold change in group 2 has an estimated p-value of 0.03, nevertheless, breadth is very variable between individuals and in group 2 there seem to be 2 outliers with considerable decrease in breadth (which were highlighted in the t-SNE plots), thus we have not put too much emphasis on this finding. These two individuals are now also highlighted in the plots of breadths, and we have added as a last sentence on the results on breadth:

"Overall, there was no dramatic change in breadths between both time points, which aligns with the immune fingerprint analysis in Figure 2. There was a small decreased average breadth in group 2 driven by 2 of the three individuals whose samples did not cluster for immune-fingerprinting."

> Figure 3. This is the first time protected vs. non-protected result appears in the analysis. Why not from the start and why not volcano plots as shown in Figure 1 for protected vs. non-protected?
>
> Categorizing antigens as low/middle/high then showing numbers of antigens in box plots seems a very counter-intuitive way of presenting the results for multi-dimensional data, much less familiar than volcano plots. Can this be justified?

We thank reviewer 2 for this comment, which greatly helped us to structure our Results. We agree that the plot on magnitudes provided only weak additional information compared to plots of breadth of response, thus for clarity, we have removed these plots.

Results have been re-ordered, the protected individuals are now shown in earlier figures, and the volcano plots of the protected group (now Figure 5A-B, previously Figure 5C-D) now follow the volcano plots of the different dose groups (now Figure 4), for better clarity. In addition, we have moved the volcano plot showing the increase in immunogenicity from baseline to after immunization in the protected group to the main article (previously in the supplement) (Figure 5C). Finally, the analysis previously shown in Figure 3 has now been restructured as follows. Figure 3A-B is now a separate figure (Figure 3B-C) in which we also included breadth before immunization for each individual (Figure 3A), Figure 3D-E on the magnitude of response have been removed and Figure 3C is now a separate figure (Figure 6).

> Figure 4. I do not understand how the t-SNE plots further probe the finding of breadth not increasing. This is claimed as the objective, but the two ideas are not further linked in the description of results.

We thank reviewer 2 for that comment. The Results restructuring puts the t-SNE results at the very beginning, followed by the results on breadth in each group, which hopefully makes it clearer. With this order, the t-SNE analysis is the first analysis, displaying the results of thousands of signal intensities onto two dimensions, and giving first indications that the patterns of humoral immune response are person specific and not drastically modified by immunization. The following analysis of breadth of humoral immune response provides additional information on the number of reactive antigens per individual and time point, and highlights the heterogeneity in breadth between individuals and a moderate change in breadths following immunization. We hope that the restructuring of our Results conveys this message better than our previous version.

Additionally, we gave more details on the t-SNE analysis at the beginning of the second paragraph of the section "Tanzanian male adults recognize a high diversity of Pf proteins":

"First, we examined the antibody profiles for each volunteer individually and the results of the paired samples are presented in the heatmap (Figure 2A). \[...\] The t-SNE algorithm estimates the probability distribution of neighbors around each point, i.e. it models the set of points which are closest to each point*."*

> I have questions on the sentence \"The number of antigen features recognized in at least 80% of the protected group (4 out of 5 individuals) was higher than in the unprotected group (27 out of 33 individuals) 2 weeks after 281 last immunization (383 reactive antigens in the protected group versus 58 in the unprotected\".
>
> Why pick that 80% to test in comparison with the unprotected group? There is a very confident p value to get out of a comparison of 4 individuals with another group (2\*10\^-16). I cannot completely follow the description of the analysis, but I doubt that such a p value can be gained from a well justified significance test in such a small group.

Yes, 80% has been taken as an arbitrary threshold, and we agree that this should be clear to the reader. We have now included results with a threshold of 60% and a threshold of 100% (antigen recognized in all sample of the group) as a supplementary figure (Figure 5---figure supplement 2). The test and corresponding p-value refer to comparing two proportions (383/2804 compared to 58/2804, 2804 being the total number of antigens) and thus does not include sample size. But we agree with reviewer 3 that this p-value could be misleading if we don't address the issue of small sample size. We did specify in the text that these results are very sensitive to the small number of protected individuals. In addition, to highlight the uncertainty due to small sample size in the protected samples, we have now added an analysis taking a bootstrap sample of n=5 for both protected and unprotected group, repeating 1000 times (Figure 7---figure supplement 1).

We have also added the following text in the second paragraph of the section entitled "Breadth of humoral immune response in protected individuals":

"The trend for higher common antigens in the protected group compared to the unprotected group was also noticeable for different thresholds, comparing antigens reactive in at least 60% or in 100% of the samples in a given group (Figure 7---figure supplement 1). \[...\] Consistent with previous analyses above, we find a higher number of common antigens in the protected compared to the unprotected group, although uncertainty due to small sample size is inevitable (Figure 7---figure supplement 1)."

> A more transparent and simple analysis is strongly suggested. A volcano plot showing distributions of p values and effect sizes would be better, and this has been missed out in Figures 1 and 2.

We agree with this comment, and as results have been re-ordered, the volcano plots of the protected group (now Figure 5A-B, previously Figure 5C-D) are now following the volcano plots of the different dose groups (now Figure 4), for better clarity. In addition, we have moved the volcano plot showing the increase in immunogenicity from baseline to after immunization in the protected group to the main article (previously in the supplement) (Figure 5C). We agree that it is crucial that all analysis is transparent on the uncertainty due to the low sample size in the protected group. Including effect sizes was a great suggestion, and we have added them as supplementary figures for the volcano plots for immunogenicity per dose group (Figure 4---figure supplement 1), the volcano plots comparing protected versus non-protected (Figure 5---figure supplement 1), and mentioned them where relevant in the Results (in legends of Figure 4 and 5).

> Antibodies to AMA1 are the \"second most significant increases\" but text doesn\'t cover details for the most significant (i.e. PfEMP1). The unadjusted p value is 0.02 and 0.0002 but adjusted p values are 0.42 and 0.26. This does not seem to fit with the previous text, and I feel the whole area of significance testing here needs more clarity.

We thank reviewer 2 for pointing this sentence out. We agree that this sentence was not relevant in the paragraph, and we have removed it. Restructuring the Results moved this paragraph, and it has been modified to hopefully increase clarity.

> Figure 5. Volcano plots are back, but again they are not showing a comparison with protected vs. non-protected but rather pre/post divided for protected vs. non-protected. The sets above of reactive antigens pre (a) and post (b) seem to imply that as much difference may have been in the pre-vaccination reactivity as in the post. Can this be clarified?

All reviewer's comments made it clear that our Results should be heavily restructured, and restructuring has been described in the previous response to comments.

The volcano plots are now higher up in the Results, and the volcano plot showing the increase in reactivity in the protected group has now been added (Figure 5C). The difference in the signal intensities in protected versus non-protected group in the post-vaccination samples is higher and more significant than in the pre-vaccination samples. Nevertheless, the text corresponding to this analysis has been modified as it was not the intention to emphasize on this result. Adding the effect sizes was a great suggestion to highlight the uncertainty of those results due to small sample size.

The volcano plot of the difference in the antigen increase after immunization from baseline between the protected and unprotected group is kept as a supplementary plot, but mentioned as followed in the Results:

"No antigen showed an increase in reactivity (delta) significantly higher in the protected group (Figure 5---figure supplement 2)."

The corresponding paragraph, which is now the third paragraph of the section "Moderate increase in antigen recognition following immunization with PfSPZ Vaccine" has been shortened and modified. Among other modifications, we added the following sentence:

"Nevertheless, the sample size of the protected group is low (n=5), and considering the low effect size measured by Cohen's distance (Figure 5---figure supplement 1), no strong argument for association with protection of these four antigens can be made from this analysis."

> Taken together I do not accept the key conclusion in the Abstract that antibodies to PfEMP1 and AMA1 were the key mediators of protection here. I would also be puzzled from an a priori perspective as sub-unit vaccines based on AMA1 have not been highly protective whereas in contrast PfSPZ has, and it is hard to accept this is primarily due to AMA1 responses.

This is a critical observation from the reviewer, the statement was too strong, and we thank the reviewer for being critical of this, as we do not wish to make too strong a statement based on our data. Additionally to the modifications made in the Results as mentioned above, we modified the Discussion to reduce the length of discussion on associations of protection and hopefully highlight the preliminary aspect of those results. The mention of the 4 identified antigens is now reduced to these two sentences:

"Although we cannot conclude on correlates of protection from this study, \[...\] IgG specific to AMA1 and 3 variants of PfEMP1 were higher before CHMI in protected versus non-protected volunteers. The three identified PfEMP1 antigens had higher levels in the protected individuals at baseline, indicating that higher levels of naturally primed, pre-existing PfEMP1 antibodies might be able to cross-react with other PfEMP1 proteins during CHMI".

> Reviewer 3:
>
> \[...\] Results: This section seems a bit unclear in its focus and explanation. Based on the Introduction, I was expecting to see results showing change in responses trying to target vaccine specific responses and impact pre-existing immunity may have on these responses. Thus I was expecting clear figures with defining degree of pre-existing exposure (and clear explanation and rationale on how this is defined; was this only defined by array responses or was there another measure to attempt to capture an individual\'s pre-existing exposure -- clinical or immunological; have these definitions been validated prior) and how PfSPZ vaccination changed this response compared to similar controls, within an individual, and even though the numbers are small for those protected, if that change in IgG profile(s) can be seen in protected versus non-protected. I believe Figure 3 panels are attempting to do this but find it hard to track clearly the story being told and the relevance on a bigger scale as it\'s discussed later on in the paper.

We thank the reviewer for this critical comment, which has helped us restructure our analysis. We have given more specification on the exclusion criteria of the clinical study, highlighting that volunteers should have no history of malaria over the 5 previous years and were parasite free at the start of the trial. The first section of the Results, "Study volunteers and serum sampling", now includes these specification:

"All volunteers included in the study had no parasitemia at the start of the study (measured by thick blood smears TBS) and no parasitemia before CHMI (measured by TBS and qPCR) (Jongo et al., 2018). Additional exclusion criteria included history of malaria in the previous 5 years or antibodies to PfEXP1 by ELISA above a threshold level (Jongo et al., 2018) associated with recent infection by CHMI (Shekalaghe et al., 2014)."

Figure 3 has now been split and edited. The Results section now starts with the microarray heatmap and t-SNE plot showing the overall response at baseline and following immunization, highlighting the person specific immune fingerprint prior to immunization and the overall unchanged immune fingerprint post-immunization for individuals across the groups regardless of protection level. These results are followed by the plots of breadth of response, before going into changes in antibody levels following immunization and between protection level (volcano-plots) and finally differences between the protected and unprotected groups in the proteins recognized.

The new structure of the Results hopefully makes it easier for the reader to identify the preexposure levels earlier on in the analysis, and observe the changes in the humoral immune response induced by vaccination and differences per protection level.

> Discussion: This section goes into the individual complexity of the array signatures even prior to vaccination, but would be interested to see if there was further analysis into age, prior residence, occupation, known malaria exposure, etc impacted this initial signature rather than assuming all male participants coming into the study were of equal prior malaria exposure.

We thank reviewer 3 and agree with this comment. We agree that other covariates such as age, malaria exposure or residence would be very interesting to investigate. We initially intended to extend our analysis to potential demographic covariates. However, we realized that given the available information on the individuals in the clinical trial, we were unable to make any distinctions between volunteers and decided to keep them as an a priori homogeneous population. We have expanded our Discussion to include this limitation as follows:

"As information on the volunteers was limited, and as per design the study selected an apparently homogeneous population, it was impossible in the current analysis to examine associations of immune responses to different parasite or host factors. \[...\] Given the complexity and personalized immune response, we expect that much larger sample size, or a population meta-analysis, would be needed to identify any pattern of humoral response associated with host and parasite factors."

In addition, we added more specifications on the volunteers in the Materials and methods, including the inclusion criteria to select malaria-negative patients, and the following paragraph:

"The 36 volunteers were healthy, adult males between 18-35 years old, with no parasitemia at the start of the study(measured by TBS and antibodies to PfEXP1 by ELISA), no history of malaria episodes over the last 5 years, and no parasitemia before CHMI (measured by TBS and qPCR) (Jongo et al., 2018). They were all students in Dar Es Salaam at the time of the study, however home town."

> The interesting impact from this research, I believe, is this assessment of possible pre-vaccination imprinting and what can we learn from this to improve vaccine strategies, including PfSPZ vaccine. I believe more should be focused on this given the results presented really had no clear post vaccination signature seen and protected vs. unprotected numbers were extremely small for wider conclusions on possible markers of protection. Exploring how different individuals with perhaps very similar exposure backgrounds come into a vaccine trial and if a vaccine can alter this pre-existing baseline to promote benefit is crucial to vaccine success and worth focusing more clearly on.

We thank reviewer 3 for this suggestion. We agree that no clear signature of protection was found, and we have reduced the paragraph discussing the potential association of the four proteins with protection highlighting the uncertainty around those findings (Discussion). We also highlighted that any signature of protection (single antigen reactivity and breadth) is based on a very small sample size and cannot be considered as a wider conclusion on possible markers or correlates of protection.

The Discussion now focuses primarily on the natural immune imprinting in pre-exposed individuals, and the potential impact on vaccine-induced protection. The third and fourth paragraphs would be the main paragraphs in the Discussion on natural imprinting. We have done additional literature research to contextualise in a broader view on the natural imprinting across different pathogens.

Additionally, our concluding paragraph hopefully better articulates the implications of our findings:

"Further reduction and eventual elimination of malaria requires significant investment and research and development of new tools, including vaccines or other immune therapies (Greenwood, 2008). \[...\]Without further fundamental studies, additional hurdles for future vaccine trials remain in regards to the validity of extrapolating vaccine outcomes from trials in naïve cohorts to pre-exposed populations and different age groups."
